Plasma and platelet von Willebrand factor defects in uremia.
OBJECTIVE
Several mechanisms have been proposed to explain the prolonged bleeding times and clinical bleeding in chronic renal failure. Recent evidence has implicated an abnormality in the structure or function of the von Willebrand factor or in its interaction with uremic platelets. We investigated this factor in 11 patients with chronic renal failure.


METHODS
Blood samples for cell counts, chemistries, and coagulation studies were obtained from 11 patients with chronic renal failure and prolonged bleeding times. Concentrations of von Willebrand factor antigen and ristocetin cofactor activity were determined in plasma and platelets. Multimeric analysis of von Willebrand factor in plasma and platelets was conducted. In eight cases, the platelets of uremic patients were purified, and the thrombin- and ristocetin-induced binding of normal von Willebrand factor to these platelets was examined.


RESULTS
The mean plasma von Willebrand factor antigen and activity (ristocetin cofactor assay) were elevated 2.77 mu/ml and 1.88 mu/ml, respectively (normal, 1.01 mu/ml and 1.07 mu/ml, respectively). The ratio of activity to antigen in uremic plasma was 0.67 (normal, 1.05). The mean platelet von Willebrand factor antigen and activity in the uremic patients was decreased (0.26 and 0.50 mu/10(9) platelets, respectively) compared with normal patients (0.46 and 0.93 mu/10(9) platelets, respectively). The oligomeric structure of the uremic plasma von Willebrand factor lacked the largest multimers. Collection of the blood for analysis in several protease inhibitors and/or EDTA did not change the multimeric structure. The von Willebrand factor multimeric structure of platelets from uremic patients was normal. The ristocetin-induced platelet aggregation of the uremic platelet-rich plasma was decreased compared with normal plasma samples. Thrombin and ristocetin-induced binding of normal von Willebrand factor to uremic patients' platelets was indistinguishable from the binding to normal platelets.


CONCLUSIONS
These data suggest that the uremic platelet-binding sites for von Willebrand factor are intact and that the defect in ristocetin-induced platelet aggregation is most likely plasmatic in nature. At least one plasmatic defect was the observed reduction or absence of the largest plasma von Willebrand factor multimer in uremic patients. The platelet von Willebrand content was significantly decreased. These defects may play a role in the prolonged bleeding time and the clinical bleeding observed in patients with uremia.
Gralnick
H R
HR
Clinical Pathology Department, National Institutes of Health 20892.
McKeown
L P
LP
Williams
S B
SB
Shafer
B C
BC
Pierce
L
L
D001760:Bleeding Time; D001792:Blood Platelets / Q000378:metabolism*; D002847:Chromatography, Agarose; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood; D008970:Molecular Weight; D010974:Platelet Aggregation / Q000187:drug effects; D010976:Platelet Count; D011485:Protein Binding / Q000187:drug effects; D012310:Ristocetin / Q000494:pharmacology; D014511:Uremia / Q000097:blood*; D014841:von Willebrand Factor / Q000032:analysis* / Q000378:metabolism
D014841:von Willebrand Factor; D012310:Ristocetin